<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429272</url>
  </required_header>
  <id_info>
    <org_study_id>LIBR 2011-002</org_study_id>
    <nct_id>NCT01429272</nct_id>
  </id_info>
  <brief_title>Minocycline and Aspirin in the Treatment of Bipolar Depression</brief_title>
  <acronym>Minocycline</acronym>
  <official_title>Minocycline and Aspirin in the Treatment of Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laureate Institute for Brain Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laureate Institute for Brain Research, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether minocycline and aspirin are effective in
      the treatment of depression in individuals with bipolar disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abstract:

      New medication classes are needed to improve treatment effectiveness in the depressed phase
      of bipolar disorder (BD). Extant evidence suggests that BD is not only characterized by
      reduced monoaminergic signaling, but also by neural changes such as dendritic remodeling,
      demyelination, and glial and neuronal cell loss. These changes have been hypothesized to
      result from chronic inflammation, based partly on convergent evidence that proinflammatory
      cytokines are elevated in depressed patients with BD. The principal aims of the proposed
      research is to evaluate the antidepressant efficacy in bipolar depression of minocycline, a
      drug with neuroprotective and immune-modulating properties, and of aspirin, at doses expected
      to selectively inhibit cyclooxygenase 1 (COX-1), within the context of a randomized,
      double-blind, placebo-controlled, parallel-group clinical trial following a 2 x 2 design.

      Specific Aims Specific Aim 1: To evaluate the efficacy of augmentation therapy with
      minocycline and/or aspirin for bipolar depression.

      The investigators will test the hypothesis that compared with placebo, participants receiving
      minocycline and/ or aspirin will show a greater treatment response rate (defined as a &gt;50%
      increase on the MADRS for the final two consecutive visits).

      Specific Aim 2: To investigate the relationship between the response to minocycline, aspirin
      and markers of inflammation (serum concentrations of IL-6 and CRP).

      The investigators will test the hypotheses that: a) minocycline treatment will reduce
      inflammation to a greater extent than placebo; b) during minocycline treatment the change in
      inflammatory cytokine expression will correlate with the change in depression ratings; c) the
      baseline elevation of inflammatory markers will predict greater antidepressant response to
      minocycline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Response</measure>
    <time_frame>Six weeks</time_frame>
    <description>Response to treatment defined as a &gt;50% decrease in Montgomery-Asberg Depression Rating Scale scores for the final two consecutive visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission Rate</measure>
    <time_frame>Six weeks</time_frame>
    <description>Remission defined as a score of &lt;11 on Montgomery-Asberg Depression Rating Scale scores for the final two consecutive visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Bipolar Disorder Depression</condition>
  <arm_group>
    <arm_group_label>Placebo &amp; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for minocycline &amp; placebo for aspirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>minocycline &amp; aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minocycline 100mg PO BID for 6 weeks &amp; Aspirin 81 mg PO BID for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>100 mg po bid for 6 weeks</description>
    <arm_group_label>minocycline &amp; aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>81 mg po bid for 6 weeks</description>
    <arm_group_label>minocycline &amp; aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo for minocycline and/or aspirin</description>
    <arm_group_label>Placebo &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        One hundred and twenty male or female outpatients between 18 and 65 years of age, who meet
        DSM-IV-TR criteria for BD (type I or II or NOS) and for a current major depressive episode
        will be recruited. The depressive syndrome must have been present for at least 4 weeks and
        the minimum threshold for depression severity will be set at a Quick Inventory of
        Depressive Symptomatology (QID-C16) score &gt;10. Subjects will provide written informed
        consent as approved by the Western Institutional Review Board.

        Exclusion Criteria:

        (a) Illness onset after 40 years of age; (b) serious risk of suicide; (c) current delusions
        or hallucinations sufficient to interfere with the capacity to provide informed consent;
        (d) current manic symptoms of sufficient severity to pose a substantial risk of the
        development of a manic episode; (e) current treatment with more than four psychotropic
        medications; (f) medical illness including hepatic impairment, renal dysfunction, bleeding
        diatheses, cerebrovascular disease, hypertension or diabetes mellitus that is inadequately
        controlled by diet and/or medication, or known active peptic ulcer disease; (g) abuse of
        drugs or alcohol within the preceding 6 months, or substance dependence within the last
        year; (h) daily alcoholic beverage consumption equivalent to &gt;3 oz. of alcohol; (i) known
        allergies or hypersensitivities to tetracycline antibiotics, aspirin or other NSAIDs; (j)
        current use of drugs that could increase the risks associated with aspirin or minocycline
        administration, (k) chronic infection, (l) use of antibiotics, (m) pregnant or nursing
        women, (n) asthma which in the opinion of the investigator would increase the likelihood of
        an asthmatic attack, and (o) regular use of steroidal or non-steroidal anti-inflammatory
        medications (occasional use of NSAIDS was allowed).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheldon Preskorn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laureate Institute for Brain Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Department of Psychiatry</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laureate Institute for Brain Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136-3326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cri-research.net/</url>
  </link>
  <link>
    <url>http://www.laureateinstitute.org/</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <results_first_submitted>September 7, 2017</results_first_submitted>
  <results_first_submitted_qc>October 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2017</results_first_posted>
  <last_update_submitted>December 13, 2017</last_update_submitted>
  <last_update_submitted_qc>December 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Minocycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo &amp; Placebo</title>
          <description>Placebo for minocycline &amp; placebo for aspirin
placebo: placebo for minocycline and/or aspirin</description>
        </group>
        <group group_id="P2">
          <title>Minocycline &amp; Aspirin</title>
          <description>Minocycline 100mg PO BID for 6 weeks &amp; Aspirin 81 mg PO BID for 6 weeks
Minocycline: 100 mg po bid for 6 weeks
Aspirin: 81 mg po bid for 6 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo + Minocycline</title>
          <description>placebo aspirin + active minocycline</description>
        </group>
        <group group_id="P4">
          <title>Placebo + Aspirin</title>
          <description>placebo minocycline + active aspirin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo &amp; Placebo</title>
          <description>Placebo for minocycline &amp; placebo for aspirin
placebo: placebo for minocycline and/or aspirin</description>
        </group>
        <group group_id="B2">
          <title>Minocycline &amp; Aspirin</title>
          <description>Minocycline 100mg PO BID for 6 weeks &amp; Aspirin 81 mg PO BID for 6 weeks
Minocycline: 100 mg po bid for 6 weeks
Aspirin: 81 mg po bid for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo + Minocycline</title>
          <description>placebo aspirin + active minocycline</description>
        </group>
        <group group_id="B4">
          <title>Placebo + Aspirin</title>
          <description>placebo minocycline + active aspirin</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="31"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="10.4"/>
                    <measurement group_id="B2" value="40.8" spread="9.7"/>
                    <measurement group_id="B3" value="44.8" spread="8.7"/>
                    <measurement group_id="B4" value="40.6" spread="10.2"/>
                    <measurement group_id="B5" value="41.5" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery-Asberg Depression Rating Score</title>
          <description>Range of scores (total) = 0-60. Higher scores indicate more depressive symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.2" spread="6.2"/>
                    <measurement group_id="B2" value="28.0" spread="5.7"/>
                    <measurement group_id="B3" value="27.2" spread="5.2"/>
                    <measurement group_id="B4" value="25.9" spread="6.5"/>
                    <measurement group_id="B5" value="27.8" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Measure of Inflammation using the C-Reactive Protein (CRP) measurement</title>
          <description>Measure of inflammation</description>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.4" spread="5.3"/>
                    <measurement group_id="B2" value="8.2" spread="12.9"/>
                    <measurement group_id="B3" value="4.3" spread="5.5"/>
                    <measurement group_id="B4" value="4.5" spread="4.9"/>
                    <measurement group_id="B5" value="5.6" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interleukin 6 (IL-6)</title>
          <description>Pro-inflammatory cytokine.</description>
          <units>pg/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" spread="0.5"/>
                    <measurement group_id="B2" value="1.0" spread="0.7"/>
                    <measurement group_id="B3" value="0.9" spread="0.5"/>
                    <measurement group_id="B4" value="1.1" spread="0.7"/>
                    <measurement group_id="B5" value="1.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treatment Response</title>
        <description>Response to treatment defined as a &gt;50% decrease in Montgomery-Asberg Depression Rating Scale scores for the final two consecutive visits.</description>
        <time_frame>Six weeks</time_frame>
        <population>Note numbers do not match the participants flow because participants who did not return for at least one post treatment visit could not be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Placebo</title>
            <description>Placebo for minocycline &amp; placebo for aspirin
placebo: placebo for minocycline and/or aspirin</description>
          </group>
          <group group_id="O2">
            <title>Minocycline &amp; Aspirin</title>
            <description>Minocycline 100mg PO BID for 6 weeks &amp; Aspirin 81 mg PO BID for 6 weeks
Minocycline: 100 mg po bid for 6 weeks
Aspirin: 81 mg po bid for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Minocycline</title>
            <description>placebo aspirin + active minocycline</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Aspirin</title>
            <description>placebo minocycline + active aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Response</title>
          <description>Response to treatment defined as a &gt;50% decrease in Montgomery-Asberg Depression Rating Scale scores for the final two consecutive visits.</description>
          <population>Note numbers do not match the participants flow because participants who did not return for at least one post treatment visit could not be included in the analysis.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Remission Rate</title>
        <description>Remission defined as a score of &lt;11 on Montgomery-Asberg Depression Rating Scale scores for the final two consecutive visits.</description>
        <time_frame>Six weeks</time_frame>
        <population>Note numbers do not match the participants flow because participants who did not return for at least one post treatment visit could not be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo &amp; Placebo</title>
            <description>Placebo for minocycline &amp; placebo for aspirin
placebo: placebo for minocycline and/or aspirin</description>
          </group>
          <group group_id="O2">
            <title>Minocycline &amp; Aspirin</title>
            <description>Minocycline 100mg PO BID for 6 weeks &amp; Aspirin 81 mg PO BID for 6 weeks
Minocycline: 100 mg po bid for 6 weeks
Aspirin: 81 mg po bid for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Minocycline</title>
            <description>placebo aspirin + active minocycline</description>
          </group>
          <group group_id="O4">
            <title>Placebo + Aspirin</title>
            <description>placebo minocycline + active aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Remission Rate</title>
          <description>Remission defined as a score of &lt;11 on Montgomery-Asberg Depression Rating Scale scores for the final two consecutive visits.</description>
          <population>Note numbers do not match the participants flow because participants who did not return for at least one post treatment visit could not be included in the analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo &amp; Placebo</title>
          <description>Placebo for minocycline &amp; placebo for aspirin
placebo: placebo for minocycline and/or aspirin</description>
        </group>
        <group group_id="E2">
          <title>Minocycline &amp; Aspirin</title>
          <description>Minocycline 100mg PO BID for 6 weeks &amp; Aspirin 81 mg PO BID for 6 weeks
Minocycline: 100 mg po bid for 6 weeks
Aspirin: 81 mg po bid for 6 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo + Minocycline</title>
          <description>placebo aspirin + active minocycline</description>
        </group>
        <group group_id="E4">
          <title>Placebo + Aspirin</title>
          <description>placebo minocycline + active aspirin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Savitz; Principal Investigator</name_or_title>
      <organization>Laureate Institute for Brain Research</organization>
      <phone>918 502 5104</phone>
      <email>jsavitz@laureateinstitute.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

